艾博抗(上海)贸易有限公司(Abcam上海办事处) 品牌商

15 年

手机商铺

商家活跃:
产品热度:
自营

Abcam

抗体/试剂

已认证
品牌介绍
Abcam公司成立于1998年,位于英国的剑桥科学园,是世界上最有名的抗体供应商之一。Abcam以优质、齐全的产品、完善的网络支持功能和强大的技术支持队伍得到全球客户的认可和赞誉。并在2004年获得了对于生物界公司不可多得的英女王奖,拥有很好的知名度和口碑。
自营

EPITOMICS

抗体

已认证
品牌介绍
EPITOMICS 公司总部位于美国加利福尼亚州Burlingame。公司独家拥有开创性的兔单克隆抗体技术(RabMab)的全球专利,并利用这一核心技术开发生产高质量的兔单克隆抗体产品,目前已广泛应用于科研和诊断领域。鼠单克隆抗体技术自70年代问世后,被迅速应用于医学和基础生物学的各个领域,在诊断试剂、临床治疗和蛋白芯片等方面形成数百亿计的巨大产业,因此,其发明者在1984年获得诺贝尔医学与生理学奖。与传统鼠单抗相比,兔单抗(RabMab)对抗原具有更高的亲和力、能识别更多的抗原表位、具备更高的灵敏度,使本底更低。因而在免疫学检测和抗体药物领域具有更大的应用开发潜力。Epitomics 公司产品:◎兔单克隆抗体(Rabbit antibody)◎抗体试剂盒(Antibody kits 及sampler kits--研究某一特定通路的常用抗体组合)◎免疫组化试剂盒(IHC kits):一抗、染色及检测试剂盒、二抗◎ELISA 试剂盒(ELISA kit)◎Support Products--对照细胞裂解液(control cell lysates)◎客户定制抗体服务
自营

Biovision

试剂

已认证
品牌介绍
BioVision 公司是世界顶尖的细胞凋亡和信号传导产品生产商,产品包括检测试剂盒,抗体及重组蛋白,涵盖了细胞凋亡、细胞信号传导和细胞因子研究的各个方面。凋亡产品包括Annexin V 试剂盒、半胱天冬氨酸蛋白酶(Caspases)试剂盒及底物和抑制剂、线粒体膜电位试剂盒、梯状DNA 电泳和TUNEL 试剂盒、凋亡诱导剂、凋亡相关抗体和化学品、细胞增殖检测试剂盒等。Abcam于2021年收购了BioVision,您可以直接在 Abcam 购买 BioVision 产品。自 2022 年 2 月 15 日起,Abcam 将独家销售 BioVision 产品。
品牌商

艾博抗(上海)贸易有限公司(Abcam上海办事处)

入驻年限:15 年

  • 联系人:

    Abcam

  • 所在地区:

    上海 浦东新区

  • 业务范围:

    ELISA 试剂盒、抗体、试剂

  • 经营模式:

    经销商

在线沟通

公司新闻/正文

Abcam acquires Firefly BioWorks to expand capabilities in multiplex analysis

人阅读 发布时间:2015-02-11 15:33

Cambridge UK, 21 January, 2015: Abcam plc, a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire the entire issued share capital of Firefly BioWorks Inc ("Firefly") (“the Acquisition”) on a cash-free/debt-free basis for £18.5m ($28.0m). The consideration, which is payable in cash on completion, will be funded from Abcam’s existing resources [1].

Firefly has developed a novel multiplex assay platform for the detection of biomarkers, based on a microfabrication technology developed by the founders at Massachusetts Institute of Technology and has developed its first product for detection of microRNAs (miRNAs). Firefly has 15 employees and is based in Cambridge, Massachusetts.

The Acquisition fits well with Abcam’s strategy outlined in September to establish new growth platforms and supports the Company's mission to enable scientists to discover more. Firefly will strengthen Abcam’s fast growing Kits and Assays business by adding an IP-protected, multiplex assay capability. miRNA is one of the fastest growing areas of biomarker and scientific research and this type of nucleic acid detection and measurement is rapidly growing in importance to Abcam’s life science consumers. Abcam and Firefly also see further potential to combine Abcam’s proprietary RabMAb® technology with Firefly’s assay capability to provide multiplex protein measurement.

After an initial period of modest investment, Firefly is expected to generate attractive returns in the longer term.

 

Alan Hirzel, CEO, Abcam, commented:

“The acquisition of Firefly represents a compelling strategic fit for Abcam, expanding our Kits and Assays business into the new areas where life science researchers tell us they have the greatest needs. RNA is one of the hottest areas in science for our consumers and we are excited about the scientific and commercial potential in what is a new product area for Abcam. We are also delighted to be working with our new colleagues at Firefly to offer researchers access to a novel technology that will enable them to assess the role of miRNA in a broad range of areas including epigenetics and cancer biomarker discovery, as well as generally across biological research. We also look forward to combining it with our RabMAb technology to bring new products to market over the forthcoming years.”

 

Davide Marini, CEO of Firefly commented:

“Firefly was founded upon the vision of integrating bioinformatics with intelligent assays and has great cultural similarities with Abcam. Our combined companies have a tremendous opportunity to develop novel assay products which will accelerate the pace of scientific discovery.”

 

Find out more about our multiplex assay technology

 

[1] This announcement, including any information included or incorporated by reference in this announcement, may contain forward-looking statements (including words such as "believe", "expect", "estimate", "intend", "anticipate" and words of similar meaning) which are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Abcam group. All statements other than statements of historical facts may be forward-looking statements and should not be treated as guarantees of future performance. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Abcam group, and there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These forward-looking statements speak only as at the date of this announcement and accordingly undue reliance should not be placed on such statements. The Abcam group does not assume any obligation to, and does not intend to, revise or update these forward-looking statements, except as required pursuant to applicable law.

 

For further information please contact:

 

Abcam + 44 (0) 1223 696 000
Alan Hirzel, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
Laura Taylor – Investor Relations

 

J.P.Morgan Cazenove - Nominated Adviser & Joint Corporate Broker + 44 (0) 20 7742 4000
James Mitford / Alex Bruce - Nominated Adviser

 

Peel Hunt LLP - Joint Corporate Broker + 44 (0) 20 7418 8900
Clare Terlouw / Jock Maxwell MacDonald – Corporate Broking

 

Brunswick +44 (0) 20 7404 5959

上一篇

abcam 品牌形象变更 请继续支持正品行货 获得品质保证

下一篇

Abcam羊绒衣,冬日里带给您温暖

更多资讯

询价列表

暂时没有已询价产品

快捷询价 发送名片
    当你希望让更多商家联系你时,可以勾选后发送询价,平台会将你的询价消息推荐给更多商家。